The important questions to be answered in the course of decision-making in patients with Graves' ophthalmopathy include the following: 1. Is the eye problem owing to Graves' ophthalmopathy? If not, the cause of the eye problem must be sought. 2. Does the patient have serious medical problems apart from the thyroid and the eyes? Define type and severity, and risk to life and well-being. Do they preclude anesthesia or steroid therapy? 3. Is the patient euthyroid? Define thyroid abnormality and treat. 4. Is the eye problem the highest medical priority for the patient and the physician? If not, treat the highest priority, then return to the eyes. 5. Which particular manifestations of Graves' ophthalmopathy are the most troublesome to the patient? Establish priorities according to need and rational order for surgical procedures. 6. How have the eyes been treated in the past? What has been successful? What side effects have resulted? In the evaluation of a patient with possible Graves' ophthalmopathy, no single clinical or laboratory feature is necessary or pathognomonic of the disorder. The sufficient findings for a diagnosis are a matter of clinical judgment. Several diagnostic tools including CT scanning, various ophthalmologic examinations, and studies of thyroid function are available. The physician must use these tools, along with clinical judgment, to establish the diagnosis with maximum certainty. Following this, the particular manifestations of the disease that are most troublesome to the patient must be carefully defined and assessed. Only then can the treatment be optimally tailored to the patient's needs.
Download full-text PDF |
Source |
---|
Mil Med Res
January 2025
Department of Endocrinology, the Second Affiliated Hospital of Naval Medical University, Shanghai, 20003, China.
Front Endocrinol (Lausanne)
January 2025
No. 1 Teaching Hospital, Norman Bethune College of Medicine, Jilin University, Changchun, Jilin, China.
Thyroid-associated ophthalmopathy (TAO), an autoimmune disease closely related to thyroid dysfunction, remains a challenging ophthalmic condition among adults. Its clinical manifestations are complex and diverse, and disease progression can lead to exophthalmos, diplopia, exposure keratitis, corneal ulceration, and compressive optic neuropathy, resulting in irreversible vision damage or even blindness. Traditional treatment methods for TAO, including glucocorticoids, immunosuppressants, and radiation therapy, often have limitations and side effects, making this disease problematic in ophthalmology.
View Article and Find Full Text PDFActa Med Indones
October 2024
Residency Program in Ophthalmology, Faculty of Medicine Universitas Indonesia - Dr. Cipto Mangunkusumo Hospital, Jakarta, Indonesia.
Background: Graves' ophthalmopathy (GO) ocular abnormalities can persist even after treatment, negatively impacting patients' psychological and social health. The Indonesian Graves' Ophthalmopathy Quality of Life (GO-QoL) Questionnaire has not been validated, hence it cannot measure patient quality of life, which is crucial to GO treatment. We aimed to provide a reliable Indonesian GO-QoL Questionnaire and identify an association between patient quality of life and clinical activity and the severity of GO.
View Article and Find Full Text PDFActa Med Indones
October 2024
School of Medicine and Health Sciences Atma Jaya Catholic University of Indonesia - St Carolus Hospital, Jakarta, Indonesia.
Numerous thyroid diseases can impact patients' lives, one of which is Graves' ophthalmopathy (GO). Graves' ophthalmopathy is a progressive thyroid-related disease that causes eye symptoms due to an autoimmune reaction targeting thyrotropin/thyroid stimulating hormone (TSH) receptors in the orbital space. This condition can be easily recognized by the patient, including exophthalmos, pain, swelling, double vision, and impaired vision.
View Article and Find Full Text PDFSci Rep
January 2025
Department of Ophthalmology, West China Hospital of Sichuan University, No.37, Guoxue Xiang, Chengdu, 610041, Sichuan, China.
The purpose of this study is to evaluate the effectiveness of intensity-modulated radiation therapy (IMRT) combined with periorbital triamcinolone acetonide injection in treating thyroid eye disease (TED) patients with active extraocular muscle but low CAS. The retrospective observational study was conducted. A total of 156 eligible patients were selected from the TED patient database of the Ophthalmology Department of West China Hospital of Sichuan University.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!